Clinical trials: Extensive Stage Small Cell Lung Carcinoma
Small Cell Lung Cancer
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when combined with carboplatin plus etoposide.
- Trial name
- NCT00702962
- Testing
- Vorinostat, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Milton S. Hershey Medical Center
Extensive Small Cell Lung Cancer
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is an aggressive cancer characterized by rapid growth, early metastasis, and a poor prognosis.
- Trial name
- NCT06406673
- Testing
- Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Cancer Hospital
SCLC, Extensive Stage
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver…
- Trial name
- SPACE (NCT04221529)
- Testing
- Atezolizumab
- Where
- 19 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- AIO-Studien-gGmbH
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT06951841
- Testing
- Liposome Irinotecan, Platinum, Tislelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Lung Cancer, Metastatic Cancer
11C Topotecan PET Imaging
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Conditions
- Lung Cancer, Metastatic Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00253461
- Testing
- computed tomography, positron emission tomography, 11C topotecan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Case Comprehensive Cancer Center
Small-cell Lung Cancer
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by…
- Trial name
- NCT05552846
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital